{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:14:41Z","timestamp":1789719281791,"version":"4.0.1"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the reduction in thrombotic events (<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content>) in patients with essential thrombocythaemia (<jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content>) treated with anagrelide versus hydroxyurea + aspirin (<jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A questionnaire was developed using 2008 <jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content> diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian <jats:styled-content style=\"fixed-case\">MPN<\/jats:styled-content> Registry on patients with myeloproliferative neoplasms. Based on <jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content> registry data, <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content>s in anagrelide\u2010treated patients (<jats:italic>n<\/jats:italic> = 139) were compared with <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>\u2010treated patients (<jats:italic>n<\/jats:italic> = 141).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients were followed up for (median) 6 yr. <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content>s were reported in significantly fewer anagrelide\u2010treated patients versus <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content> (15.1% versus 49.6%; <jats:italic>P<\/jats:italic> &lt; 0.001). Numbers of major arterial and major venous events were similar between the groups, although there were over fivefold more minor arterial and minor venous events in the <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content> group (<jats:italic>P<\/jats:italic> &lt; 0.001). While median age at diagnosis was older and length of follow\u2010up shorter in the <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content> group (<jats:italic>P<\/jats:italic> &lt; 0.05), this did not influence <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content> incidence; medication and <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content> before diagnosis only influenced <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content> incidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content>s versus <jats:styled-content style=\"fixed-case\">HU<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content> over 6 yr. Risk of <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content> after diagnosis was significantly increased if the patient had <jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content> before diagnosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12806","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T08:03:03Z","timestamp":1472112183000},"page":"106-111","source":"Crossref","is-referenced-by-count":14,"title":["Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin"],"prefix":"10.1111","volume":"98","author":[{"given":"P\u00e9ter","family":"Dombi","sequence":"first","affiliation":[{"name":"Szent Borbala County Hospital Tatab\u00e1nya Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Haematology University of Debrecen Faculty of Medicine Debrecen Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Division of Haematology Semmelweis University of Budapest Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Homor","sequence":"additional","affiliation":[{"name":"Faculty of Humanities and Social Sciences Pazmany Peter Catholic University Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Haematology University of Debrecen Faculty of Medicine Debrecen Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Karadi","sequence":"additional","affiliation":[{"name":"Department of Haematology Somogy County Kaposi M\u00f3r Teaching Hospital Kaposv\u00e1r Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Udvardy","sequence":"additional","affiliation":[{"name":"Department of Haematology University of Debrecen Faculty of Medicine Debrecen Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Egyed","sequence":"additional","affiliation":[{"name":"Department of Haematology Somogy County Kaposi M\u00f3r Teaching Hospital Kaposv\u00e1r Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.69"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404810"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.113"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.148"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.5298"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-339002"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23895"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0899-z"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-976165"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1556\/650.2016.30340"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12604"},{"key":"e_1_2_6_15_1","first-page":"354","article-title":"Novel approaches in the diagnosis and treatment of chronic myeloproliferative illnesses","volume":"67","author":"Masszi T","year":"2014","journal-title":"Magy Belorv Arch"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443770"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20646"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1218-2"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.05.014"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263319"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199804)57:4<277::AID-AJH2>3.0.CO;2-R"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12806","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:19:14Z","timestamp":1696331954000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,19]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/ejh.12806"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12806","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,19]]}}}